Brezosiran Huntington Trial Cuts Harmful Protein Sharply

Alnylam Pharmaceuticals has reported early results from the brezosiran Huntington trial, an experimental RNA interference therapy for Huntington's disease, and the findings drew attention at a research congress in Krakow, Poland. The treatment is given as a single dose into the spinal canal, a route chosen because it can reach the fluid that bathes the brain and spinal cord. Researchers measured mutant huntingtin, the faulty protein at the center of the disease, in that spinal fluid. According to Alnylam, the reductions grew stronger as the dose rose, a pattern that gave the team confidence the drug was engaging its target rather than producing a chance result.

What the early results show

In the highest dose group tested so far, patients showed a mean reduction of 60% to 64% in mutant huntingtin three months after treatment, while one individual patient reached 83%. The result was confirmed with two separate laboratory tests, which matters because a finding that survives a second method is harder to dismiss as a quirk of one assay. The trial is still in an early phase, so these figures describe a biological effect, not proof that symptoms improve. That distinction matters for families reading headlines, since lowering a protein is a step toward a treatment, not a treatment itself yet.

The data cover 48 participants across the first five dose groups, and a sixth group is now recruiting a dozen more people. Each group received a larger dose than the last, allowing researchers to watch for both stronger effects and any sign of trouble as exposure increased. Participants were adults with genetically confirmed Huntington's disease, and the study enrolled people at a stage where symptoms were already present but the disease had not advanced to its later phases. Eligible participants can move into an extension study that continues dosing twice a year for up to 36 months, giving researchers a longer view of safety and durability.

Safety data so far cover follow-up lasting up to a year, and the report describes an encouraging profile. Researchers found no dose-related rise in spinal fluid inflammatory markers, in neurofilament light chain, or in brain ventricular volume, three measures watched for signs of nerve injury or unwanted inflammation. Long-term safety remains unanswered, since the trial was not designed to answer that question at this stage. It does mean the early safety signals have not worsened as doses climbed, which is the outcome researchers look for before moving to larger studies.

Why families are watching closely

Huntington's disease is a fatal inherited disorder of the brain caused by an expanded repeat in the huntingtin gene. It gradually affects movement, thinking, and mood, and it passes from parent to child, which means a diagnosis often lands on whole families at once. More than one hundred thousand people worldwide live with symptoms, according to company estimates reported in trial coverage, and there are currently no approved treatments that change the course of the disease. Existing care manages symptoms, so a therapy that attacks the underlying protein has been a long-standing goal for researchers in the field.

Brezosiran is designed to lower all forms of the huntingtin protein, including the full-length mutant form and a shorter form known as HTT1a that researchers increasingly suspect plays a part in progression. That breadth matters because earlier approaches that lowered only part of the protein picture left open questions about whether the most damaging fragments were being reached. Dr. Blair Leavitt, a neurologist at the University of British Columbia and a principal investigator on the study, described the evidence as a promising advance for a program aimed at a disease where that kind of treatment remains unavailable. His comment, reported by Alnylam, reflects the mood among investigators rather than a verdict on clinical benefit, which only a larger controlled trial can deliver.

Alnylam plans a placebo-controlled pivotal study as the next step for the brezosiran Huntington trial next year, pending agreement with regulators, to test whether brezosiran can slow progression in adults with Huntington's disease. Details of the trial design were reported by Clinical Trials Arena. A pivotal study is the larger, controlled test that regulators weigh when deciding whether a drug should reach patients, so its design and results will matter more than any early protein reading. For now, the early data show a single spinal dose lowered the target protein substantially, the effect lasted long enough to support twice-yearly dosing, and safety signals stayed steady as doses rose. The next update to watch is the start of that pivotal study.